Korean J Pain 2019; 32(1): 1-2
Published online January 28, 2019 https://doi.org/10.3344/kjp.2019.32.1.1
Copyright © The Korean Pain Society.
Young Hoon Kim*
Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Correspondence to: Young Hoon Kim. Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea. Tel: +82-2-2258-1330, Fax: +82-2-537-1951, firstname.lastname@example.org
Received: December 11, 2018; Accepted: December 12, 2018
Chronic pain has a close relationship with several psychiatric conditions, such as anxiety, depression, and sleep disturbance. Because chronic pain is an important factor in both the occurrence and the persistence of psychiatric problems, and vice versa, its proper psychopharmacological management might be a meaningful treatment for improving patients' quality of life .
A pharmacological focus on antidepressants and anxiolytics is relatively well-known and well-established in pain management [1,2]. A ntidepressants a nd a nxiolytics could contribute to pain reduction as well as to the improvement of coexisting anxiety, depression, or sleep disturbance. When antipsychotics are used in the treatment of accompanying psychiatric conditions such as schizophrenia, major depressive disorder, and bipolar disorder, their analgesic properties may help lower the severity of chronic pain as adjuvant analgesics. However, the use of antipsychotics in pain management is still under debate, because of the low quality of evidence regarding the efficacy of antipsychotics in improving pain, sleep disturbance, depression, and anxiety.
The effect of antipsychotics has been studied in the treatment of headaches, post-herpetic neuralgia, trigeminal neuralgia, and fibromyalgia . While antipsychotics showed some potential for analgesic properties, their major adverse reactions such as extrapyramidal symptoms (acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia), anticholinergic effects, and prolactin elevation are associated with the limitation of their use, especially in the use of typical antipsychotics (the first generation antipsychotics) [3,4,5]. Nowadays, atypical antipsychotics, also referred to as second generation antipsychotics, which are known to have fewer extrapyramidal side effects and additional benefits, are available. This novel group of antipsychotics needs to be investigated for their analgesic potential.
In this issue of